-transparent.png){kind=logo}
Potential risk factors responsible for development of doxorubicin-induced congestive heart failure were examined through retrospective analysis of 4018 patient records. The overall incidence of drug-induced congestive heart failure was 2.2% (88 cases). The probability of incurring doxorubicin-induced congestive heart failure was related to the total dose of doxorubicin administered. There was a continuum of increasing risk as the cumulative amount of administered drug increased. A weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule. An increase in drug-related congestive heart failure was also seen with advancing patient age. Performance status, sex, race, and tumor type were not risk factors. These data will enable clinicians to better estimate the risk/benefit ratio in individual patients receiving prolonged administration of doxorubicin. They also provide a basis for the investigation of less cardiotoxic anthracycline analogues or for designing measures to prevent doxorubicin-induced cardiomyopathy.
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
August 1982,
Archives of internal medicine,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
September 1985,
Cancer,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
January 1997,
Transplantation proceedings,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
January 2003,
Annals of internal medicine,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
February 1991,
Surgery, gynecology & obstetrics,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
May 2006,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
October 2002,
Journal of molecular and cellular cardiology,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
January 2017,
Heart & lung : the journal of critical care,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
January 1981,
Southern medical journal,
D D Von Hoff, and
M W Layard, and
P Basa, and
H L Davis, and
A L Von Hoff, and
M Rozencweig, and
F M Muggia
January 1998,
Scandinavian cardiovascular journal. Supplement,
